je.st
news
Tag: biotech
Crowdfunding and IP in Health and Biotech Start-ups (Part 2): The JOBS Act
2015-06-26 20:46:57| Biotech - Topix.net
This is the second in a 3-part series about the use of crowdfunding in health and biotech start-ups. We started with the story of a tech start-up which set records for funding through a Kickstarter campaign, triggering the interest of entrepreneurs in capital- intensive industries .
What You May Have Missed in Biotech: Cancer-Killing T-Cells, Hope for Migraines, CRISPR Controversy
2015-06-26 15:27:27| Biotech - Topix.net
Luke Timmerman is a journalist specializing in biotechnology. He is the founder and editor of the Timmerman Report, a subscription publication for biotech insiders.
Tags: hope
missed
biotech
controversy
Nemucore raises the bar for biotech interns to produce results
2015-06-26 07:10:15| Biotech - Topix.net
WORCESTER – Mackenzi R. McHugh sits at a horseshoe-shaped table and types on a laptop computer, nearly six hours into a shift that typically starts with a scientific meeting, continues with laboratory experiments and ends with data analysis. At 20 years old, the Worcester Polytechnic Institute biology major from Corinth, Maine, is working with other interns at Nemucore Medical Innovations Inc. on projects critical to the biotechnology company.
Tags: results
bar
produce
raises
Collaborations make Seattle Genetics a safer way to play biotech
2015-06-25 10:37:14| Biotech - Topix.net
Bill Gunderson is a San Diego money manager, financial talk show host, creator of the Best Stocks Now app and editor of the Gunderson Report . He has been featured in -- or a guest on -- several national financial news sites, including Fox Business, Bloomberg, Barron's, Fortune, Forbes, and others.
Tags: make
play
seattle
genetics
OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of
2015-06-25 06:21:30| Biotech - Topix.net
Newly uplisted, small cap biotech OncoSec is making big advancements in the immuno-oncology space with its unique ImmunoPulse intratumor delivery technology. OncoSec has a market cap of only ~$100M, over $30M in cash, several Phase 2 clinical trials underway, impressive clinical data and the potential to revolutionize immuno-oncology treatment.
Tags: of
medical
heard
incorporated
Sites : [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] next »